Latest Ratios: P/E Ratio 33.1x · EV/EBITDA 8.5x · ROE 4.6%. (2004–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $35.8B | — | $48.0B | $48.5B | — | $70.7B | $66.3B | $65.6B | $66.2B | $80.2B | $75.9B |
| Enterprise Value | $33.9B | — | $47.8B | $48.3B | — | $67.4B | $63.9B | $63.9B | $71.4B | $85.4B | $79.9B |
| P/E Ratio → | 33.13 | 33.77 | 42.56 | 66.54 | — | 4717.50 | 4422.50 | 4375.00 | — | 31.64 | 150.86 |
| P/S Ratio | 2.06 | — | 2.84 | 2.82 | — | 4.52 | 4.66 | 4.74 | 4.63 | 3.29 | 5.41 |
| P/B Ratio | 0.00 | 0.00 | 2.00 | 1.92 | 0.00 | 2.76 | 2.65 | 2.67 | 0.88 | 1.07 | 7.45 |
| P/FCF | 12.72 | — | 31.02 | 41.31 | — | 32.83 | 41.72 | — | — | — | 32.48 |
| P/OCF | 10.51 | — | 22.38 | 27.42 | — | 25.93 | 32.12 | 61.29 | 137.00 | 324.64 | 22.62 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 2.83 | 2.81 | — | 4.30 | 4.49 | 4.62 | 5.00 | 3.51 | 5.69 |
| EV / EBITDA | 8.49 | — | 14.38 | 14.55 | — | 26.32 | 31.62 | 29.29 | 154.83 | 25.09 | 37.28 |
| EV / EBIT | 12.15 | — | 31.68 | 36.44 | — | 28.36 | 88.71 | — | — | 150.97 | 25.84 |
| EV / FCF | — | — | 30.86 | 41.16 | — | 31.28 | 40.20 | — | — | — | 34.18 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.6% | 44.6% | 43.6% | 42.4% | 40.2% | 41.1% | 40.2% | 38.1% | 40.4% | 24.0% | 40.2% |
| Operating Margin | 16.0% | 16.0% | 12.4% | 12.2% | 11.0% | 8.4% | 5.9% | 4.2% | -3.1% | 7.6% | 6.3% |
| Net Profit Margin | 6.3% | 6.3% | 5.4% | 4.3% | 6.6% | 11.2% | 4.8% | -6.9% | -35.4% | 10.4% | 3.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.6% | 4.6% | 3.7% | 2.9% | 4.5% | 6.9% | 2.7% | -1.9% | -6.7% | 6.0% | 4.9% |
| ROA | 2.6% | 2.6% | 2.2% | 1.7% | 2.7% | 4.1% | 1.6% | -1.3% | -4.6% | 3.3% | 1.3% |
| ROIC | 9.0% | 9.0% | 6.4% | 6.5% | 6.3% | 4.4% | 2.8% | 0.8% | -0.4% | 2.9% | 4.8% |
| ROCE | 9.1% | 9.1% | 6.7% | 6.5% | 6.0% | 3.9% | 2.5% | 0.9% | -0.5% | 2.8% | 3.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.13 | 0.12 | 0.05 | 0.04 | 0.04 | 0.01 | 0.11 | 0.17 | 0.84 |
| Debt / EBITDA | 0.65 | 0.65 | 0.96 | 0.90 | 0.41 | 0.44 | 0.55 | 0.06 | 17.22 | 3.84 | 3.98 |
| Net Debt / Equity | — | -0.08 | -0.01 | -0.01 | -0.07 | -0.13 | -0.10 | -0.07 | 0.07 | 0.07 | 0.39 |
| Net Debt / EBITDA | -0.49 | -0.49 | -0.07 | -0.05 | -0.60 | -1.30 | -1.20 | -0.75 | 11.30 | 1.54 | 1.86 |
| Debt / FCF | — | -0.69 | -0.16 | -0.15 | -7.06 | -1.55 | -1.52 | — | — | — | 1.71 |
| Interest Coverage | 15.49 | 15.49 | 6.47 | 5.69 | 19.05 | 79.20 | 16.00 | -1.32 | -19.20 | 7.65 | 30.62 |
Net cash position: cash ($4.5B) exceeds total debt ($2.6B)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | 1.43 | 1.45 | 1.56 | 1.56 | 1.63 | 1.73 | 1.64 | 1.73 | 1.90 | 1.96 |
| Quick Ratio | 0.96 | 0.96 | 0.93 | 0.90 | 0.93 | 1.08 | 1.16 | 1.03 | 1.33 | 1.19 | 1.36 |
| Cash Ratio | 0.37 | 0.37 | 0.34 | 0.31 | 0.31 | 0.48 | 0.44 | 0.21 | 0.21 | 0.72 | 0.66 |
| Asset Turnover | — | 0.41 | 0.41 | 0.40 | 0.41 | 0.37 | 0.33 | 0.33 | 0.13 | 0.22 | 0.35 |
| Inventory Turnover | 1.70 | 1.70 | 1.75 | 1.44 | 1.53 | 1.78 | 1.74 | 1.70 | 1.60 | 0.97 | 1.57 |
| Days Sales Outstanding | — | 133.64 | 123.18 | 116.86 | 119.21 | 112.17 | 126.47 | 145.73 | 134.38 | 78.54 | 128.91 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 100.0% | 1.0% | 0.9% | 100.0% | 0.6% | 0.6% | 0.8% | 0.0% | 1.2% | 1.8% |
| Payout Ratio | 43.0% | 43.0% | 50.5% | 59.7% | 36.4% | 22.6% | 57.0% | — | — | 39.4% | 265.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.0% | 3.0% | 2.3% | 1.5% | — | 0.0% | 0.0% | 0.0% | — | 3.2% | 0.7% |
| FCF Yield | 7.9% | — | 3.2% | 2.4% | — | 3.0% | 2.4% | — | — | — | 3.1% |
| Buyback Yield | 3.0% | — | 2.1% | 1.6% | — | 1.3% | 0.4% | 0.0% | 0.0% | 1.1% | 1.2% |
| Total Shareholder Yield | 100.0% | — | 3.1% | 2.5% | — | 1.9% | 1.0% | 0.8% | 0.0% | 2.4% | 3.0% |
| Shares Outstanding | — | $0 | $868M | $868M | $0 | $750M | $750M | $750M | $868M | $868M | $868M |
Seasonal Working Capital Volatility
According to current market data, EIDP trades at a TTM P/E of 33.80, which appears elevated relative to its forward P/E of 13.87, suggesting that investors are pricing in significant earnings recovery following recent seasonal volatility in the agricultural input sector.
The wide gap between trailing and forward multiples indicates that the market anticipates a normalization of earnings as the company moves past recent margin compression. While the PEG ratio of 0.24 suggests potential undervaluation, this metric may be misleading given the inherent lumpiness of agricultural revenue cycles.
Based on reported figures, EIDP's ROIC has fluctuated between -1.2% and 5.1% over the last ten quarters, reflecting the intense capital intensity required to maintain proprietary germplasm libraries while navigating the cyclical nature of the global agricultural planting calendar.
The volatility in returns on invested capital suggests that the company's ability to compound value is heavily dependent on the timing of product sales rather than consistent operational efficiency. Investors should monitor whether the pivot toward biologicals can stabilize these returns by reducing reliance on synthetic chemical cycles.
As reported in financial statements, the company's cash conversion cycle remains highly erratic, with DSO reaching as high as 290 days in 2025Q3, illustrating the significant pressure that seasonal agricultural retail credit terms place on the firm's overall working capital efficiency.
The extended collection periods suggest that EIDP effectively acts as a financier for its distribution network, which is a structural reality of the agricultural inputs industry. This reliance on long-dated receivables warrants close monitoring to ensure that credit risk does not escalate during periods of commodity price weakness.
Based on recent SEC filings, EIDP maintains a conservative debt-to-equity ratio peaking at only 0.23, which provides a substantial financial cushion against the interest rate sensitivity and cyclical demand shocks that frequently impact the broader basic materials and agricultural input sectors.
This minimal leverage profile is a key differentiator compared to peers like Bayer or Dow, allowing the company to maintain R&D spending even during down-cycles. The low debt burden suggests that the firm is well-positioned to weather potential regulatory or commodity-driven headwinds without compromising its core operations.
Data from financial statements suggests that the Price-to-Book ratio is a fundamentally flawed metric for EIDP, as it fails to capture the value of the company's proprietary germplasm and biotechnology IP, which are not fully reflected in traditional accounting book values.
Because the company's primary competitive advantage is derived from intangible biological assets rather than physical plant and equipment, the P/B ratio obscures the true replacement cost of its market position. Analysts should instead focus on EV/EBITDA or normalized free cash flow to better assess the firm's underlying earning power.
Includes 30+ ratios · 22 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTA-PA stock.
EIDP, Inc.'s current P/E ratio is 33.1x. The historical average is 38.0x. This places it at the 59th percentile of its historical range.
EIDP, Inc.'s current EV/EBITDA is 8.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.3x.
EIDP, Inc.'s return on equity (ROE) is 4.6%. The historical average is 38.2%.
Based on historical data, EIDP, Inc. is trading at a P/E of 33.1x. This is at the 59th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
EIDP, Inc.'s current dividend yield is 100.00% with a payout ratio of 43.0%.
EIDP, Inc. has 44.6% gross margin and 16.0% operating margin. Operating margin between 10-20% is typical for established companies.
EIDP, Inc.'s Debt/EBITDA ratio is 0.6x, indicating low leverage. A ratio below 2x is generally considered financially healthy.